Kornimate/medical-research-clean huggingface dataset:
liraglutide and peripheral artery disease

Conditions: Type 2 Diabetes; Peripheral Arterial Disease

Summary: stardust is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with type 2 diabetes and peripheral artery disease. the potential benefits for participants in the study include the possibility of improving peripheral perfusion with drugs that have been evaluated as effective in controlling diabetes and safe and protective for cardiovascular health. the primary outcome of the study is the change of peripheral transcutaneous oxygen tension between groups at three and six months. participants in the study will be followed for 6 months in order to evaluate the effects of liraglutide and the change of other secondary outcomes.

an 18-month extension of the follow-up will be performed for all the study population, according to guidelines and good clinical practice. the follow-up will include the glyco-metabolic parameters and the main cardiovascular risk factors, including tcpo2 assessment. data from this extended observation will be collected for additional analyses (mostly regarding the durability of the effects). individuals who will be lost during follow-up and/or discontinue or modify the glucose-lowering treatment will be excluded from the analyses.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes within at least 6 months * peripheral arterial disease documented within al least 1 year by doppler ultrasound, angio-ct or arteriography * peripheral transcutaneous oxygen pressure between 30 and 49 mmhg on anterior and/or posterior tibial arteries * hba1c 6,5-8% * treatment of diabetes with metformin, insulin and/or sulfonylurea exclusion criteria: * diagnosis of type 1 diabetes * current treatment with glp-1 receptor agonists (glp-1ras) or dipeptidyl peptidase -4 (dpp-4) inhibitors * glp-1ras allergy or intolerance * participation to other clinical studies * history of pancreatitis, thyroid disease, diabetic gastroparesis or inflammatory bowel disease * current or planned pregnancy * acute myocardial infarction and/or acute cerebrovascular disease within 14 days from the screening visit * planned revascularization procedure * renal function with estimated glomerular filtration rate (egfr) below 15 ml/min * history of cancer and/or oncological treatment within 5 years from the screening visit * current treatment with corticosteroids * psychiatric or other clinical conditions which may interfere with the study

Keywords: type 2 diabetes liraglutide transcutaneous oxygen tension peripheral arterial disease inflammation angiogenesis endothelial dysfunction diabetic microvascular complications
remplissage versus latarjet coracoid transfer for recurrent shoulder instability

Conditions: Shoulder Dislocation

Summary: this is a pilot study designed as a prospective, randomized controlled trial comparing arthroscopic bankart repair and remplissage with an open latarjet coracoid transfer for the treatment of recurrent anterior glenohumeral instability with subcritical bone loss.

presently, consensus guidelines for the surgical management of anterior glenohumeral instability are lacking. while there has been continual evolution in available arthroscopic instrumentation, this has not translated to improvements in patient outcomes. isolated arthroscopic bankart repair is often associated with unacceptably high rates of failure, with a recent systematic review identifying continued recurrence rates of 14.2%. improved recognition of bone defects and identification of critical defect sizes that contribute to recurrent instability and failed stabilization have lead to improvements in treatment algorithms. it has been widely accepted that glenoid defects exceeding 20% of anteroposterior (ap) width and humeral head defects exceeding 30% of the humeral head width contribute to recurrent instability. for defects of this magnitude, isolated arthroscopic bankart repair is insufficient in restoring joint stability, and more extensive procedures are required. this can include adding a remplissage to the arthroscopic bankart repair or open allograft reconstruction for humeral defects; or latarjet coracoid transfer for glenoid defects. however, often patients present with combined 'bipolar' bone loss, where individual defects are subcritical in size. there is increasing recognition that the presence of this combined bone loss may lead to increased rates of failure with an isolated arthroscopic bankart repair. currently, accepted treatment options for bipolar bone loss include a combined arthroscopic bankart repair and remplissage, or a latarjet coracoid transfer. while there is supportive biomechanical data for each procedure, and limited case series in the literature, there remains a paucity of high-quality evidence to guide treatment for this complex clinical scenario. consequently, we aim to perform a pilot study designed as a prospective, randomized controlled trial comparing arthroscopic bankart repair and remplissage with an open latarjet coracoid transfer.

Eligibility criteria:
inclusion criteria: * anterior shoulder instability (\>1 dislocation) * age \>14 years * evidence of a hill-sachs defect on mri or ct, * \< 20% anteroposterior glenoid bone loss exclusion criteria: * \>20% anteroposterior glenoid bone loss * significant shoulder comorbidities (i.e., osteoarthritis, previous surgery other than previous instability), active joint or systemic infection, significant muscle paralysis, rotator cuff or charcot's arthropathy, * significant medical comorbidity that may alter effectiveness of surgical intervention * major medical illness, * unable to speak french or english, * psychiatric illness that precludes informed consent, * unwilling to be followed for 2 years

Keywords: bankart repair remplissage latarjet coracoid transfer
the effectiveness of lactoferrin in the management of treatment-induced anemia

Conditions: Anemia

Summary: this will be a randomised control trial designed to test the effectiveness of lactoferrin in the management of treatment-induced anemia in patients with hematological malignancies.

chemotherapy induced anemia (cia) is a common adverse event in cancer patients reported to occur in 20-60% whilst the resulting low hemoglobin level is associated with impaired quality of life. lactoferrin (lf) is a non-haem iron-binding protein that is part of the transferrin protein family, along with serum transferrin, ovotransferrin, melanotransferrin and the inhibitor of carbonic anhydrase, whose function is to transport iron in blood serum. the aim of the study is to test the effectiveness of lf along with standard care in the management of treatment-induced anemia.

Eligibility criteria:
inclusion criteria: * patients on active treatment (chemotherapy i.e. cyclophosphamide, doxorubicin, rituximab, cisplatin carboplatin, etoposide) * ability to independently complete the questionnaires exclusion criteria: * allergy to milk * lactose intolerance * celiac disease * patient of whom chemotherapy has been interrupted for more than 2 weeks (due to adverse effects)

Keywords: hemoglobin quality of life
an observational study of pegasys (peginterferon alfa-2a) plus copegus (ribavirin) in participants with chronic hepatitis c (chc), genotype 2, 3, 1 or 4, undergoing opioid maintenance therapy

Conditions: Hepatitis C, Chronic

Summary: this prospective, multi-center, observational study will evaluate the efficacy and safety of pegasys (peginterferon alfa-2a) plus copegus (ribavirin) in participants with previously untreated chronic hepatitis c, genotype 2, 3, 1 or 4, who are undergoing opioid maintenance therapy. data will be collected from eligible participants receiving pegasys and copegus treatment as prescribed by treating physician and treatment-free follow-up period of 24 weeks.


Eligibility criteria:
inclusion criteria: * adult participants, \>/= 18 years of age * participants undergoing an opioid maintenance therapy * serologic evidence of chc prior to therapy * chc genotype 2, 3, 1 or 4 * quantifiable serum hepatitis c (hcv) ribonucleic acid (rna) * all fertile males and females receiving ribavirin must use two forms of effective contraception during treatment with study drugs and for 7 months after completion of treatment exclusion criteria: * harmful use of psychoactive substances (including excessive alcohol consumption) that precludes successful participation in the study at the discretion of the investigator * pegylated interferon, standard interferon or ribavirin therapy at any time prior to initiation of the study * co-infection with hepatitis a, hepatitis b or human immunodeficiency virus (hiv) * current diagnosis of a major depression or any psychotic disorder
the effects of valsalva maneuver on head, neck and upper extremity arterial systems

Conditions: Asymptomatic Diseases

Summary: the aim of this study is to determine the relation between arterial diameter and flow of carotis interna, brachial artery and radial artery before and after valsalva maneuver.

the aim of this study is to determine the relation between arterial diameter and flow of carotis interna, brachial artery and radial artery before and after valsalva maneuver. a total of 70 patients in preoperative period will enroll in this study. after a deep inspiration, patients will asked to exhale to a valf system with a flow pressure of 20-40 mmhg and duration of 15 seconds. during valsalva maneuver, the diameter and flow rates of carotis interna, brachial artery and radial artery will measure using ultrasound. all data will be recorded.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists score of i, ii, iii exclusion criteria: * morbid obesity (body mass index over 40) * not to participate in the study * psychiatric diseases * peripheral vascular diseases

Keywords: valsalva
rosuvastatin in rheumatoid arthritis (rora)

Conditions: Rheumatoid Arthritis

Summary: patients with rheumatoid arthritis are at increased risk of having cardiovascular deaths. the investigator's study is aimed at looking at the effects of proven cholesterol lowering treatment drug called rosuvastatin in rheumatoid arthritis patients on few cardiovascular markers. endothelial behaviour improved on treatment.


Eligibility criteria:
inclusion criteria: * patients will be selected from a high risk population of hospital clinic attendees, defined as ra greater than 5 years' disease duration, and all will be ra latex seropositive or igm rf elisa \>14iu/ml. the subjects will be of either sex and \>40 years of age. * patients should have both tender and swollen joint counts \>4 each and either a crp \>10mg/l, esr \>25mm/h or pv \>1.78. * patients on cyclosporine or other medications known to be contraindicated with this form of drug will not be enrolled. exclusion criteria: * the patient's hospital and general practice records will be scrutinised for evidence of symptomatic vascular disease. * any patient not free from vascular disease symptoms will be excluded. * in addition to evidence of symptomatic vascular disease (either previous or current), the exclusion criteria consist also of those already taking lipid-lowering therapy or those with contraindications to these therapies. * also excluded will be subjects with a total cholesterol level of \>7.5mmol/l as it might be argued that such patients merit primary prevention on the basis of dyslipidemia alone.

Keywords: rheumatoid arthritis rosuvastatin cardiovascular intima media thickness
combination chemotherapy with or without g-csf in treating patients with relapsed chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: rationale: drugs used in chemotherapy, such as fludarabine, mitoxantrone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) may kill more cancer cells. colony stimulating factors, such as g-csf, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of combination chemotherapy. it is not yet known whether giving combination chemotherapy alone is more effective than combination chemotherapy together with g-csf in treating patients with chronic lymphocytic leukemia. purpose: this randomized phase iii trial is studying giving combination chemotherapy together with g-csf to see how well it works compared to giving combination chemotherapy alone in treating patients with relapsed stage i, stage ii, stage iii, or stage iv chronic lymphocytic leukemia.

objectives: primary * compare the rate of remission, severe infections, and side effects in patients with relapsed advanced chronic lymphocytic leukemia treated with fludarabine, mitoxantrone hydrochloride, and cyclophosphamide with vs without filgrastim. secondary * compare the overall survival, progression-free survival, and quality of remission in these patients. outline: this is a multicenter, randomized study. patients are randomized to 1 of 2 treatment arms. * arm i: patients receive fludarabine iv on days 1-3, mitoxantrone hydrochloride iv on day 1, and cyclophosphamide iv on days 1-3. * arm ii: patients receive fludarabine, mitoxantrone hydrochloride, and cyclophosphamide as in arm i and filgrastim (g-csf) beginning on day 6 and continuing until blood counts recover. in both arms, treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 165 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * confirmed relapsed and advanced chronic lymphocytic leukemia (cll) * binet stage b or c disease with rapid disease progression, enlarged lymph nodes and organs, or severe b-symptoms * no prior non-response to fludarabine combination therapy patient characteristics: * ecog performance status 0-3 * life expectancy \> 6 months * no severe organ dysfunction * no other prior or concurrent neoplasm, autoimmune hemolytic anemia, or thrombocytopenia prior concurrent therapy: * no more than three previous treatment regimens for cll (fludarabine allowed)

Keywords: refractory chronic lymphocytic leukemia stage iii chronic lymphocytic leukemia stage iv chronic lymphocytic leukemia stage i chronic lymphocytic leukemia stage ii chronic lymphocytic leukemia
the effects of self-monitoring with a mobile application in heart failure

Conditions: Heart Failure

Summary: in the united states, about 40 percent of heart failure (hf) patients are readmitted within 1-year following their first admission for hf and hospitalization accounts for approximately 70 percent of the costs of hf management. as a result, the management of hf patients is evolving from the traditional model of face-to-face follow-up visits toward a proactive real-time technological model of assisting patients with monitoring and self-management while in the community. the investigators plan to test the impact of a mobile application on clinical outcomes in hf.

hf patients with a reduced ejection fraction will be randomized to the mobile application versus placebo for 12 weeks. the mobile application will provide the participants with a reminder to perform self-monitoring, a health status indicator and heart failure education for self-management. all participants will complete the minnesota living with heart failure questionnaire and self-care heart failure index. hospital admissions and mortality will also be collected.

Eligibility criteria:
inclusion criteria: * 45 years old or older * left ventricular ejection fraction \ 40% (with left atrial size \>40mm or bnp \> 200 pg/ml or nt-probnp \> 800 pg/ml) * admitted for acutely decompensated heart failure or recently discharged in the past 4 weeks. * smartphone (ios or android) with home wifi exclusion criteria: * unstable coronary syndrome within 8 weeks (unstable angina, nstemi, stemi) * primary valvular heart disease * known pericardial disease (sarcoidosis, amyloidosis, rheumatoid arthritis, lupus) * uncorrected thyroid disease * advanced renal disease (dialysis or creatinine \>4.0 mg/dl) * end-stage hf (hospice candidate, home milrinone or dobutamine) * active cancer * pulmonary fibrosis * discharge to a setting other than home

Keywords: mobile application mhealth
proarte -prostate artery to reduce the symptoms of benign prostatic hyperplasia

Conditions: Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms

Summary: this is a trial to demonstrate the superiority of prostate artery embolization (pae) over sham procedure in men with benign prostatic hyperplasia (bph) induced lower urinary tract symptoms (luts). the trial will aim to enroll 108 patients at a 2:1 allocation over a 2 year period.


Eligibility criteria:
inclusion criteria: * • men ≥45 and ≤90 years presenting with benign prostatic hyperplasia with symptoms for at least 6 months that are refractory to medical management or in whom medications are contraindicated, not tolerated, or refused. * international prostate symptom score (i-pss) score 14 or greater. * quality of life (qol) score ≥ 3 * peak urinary flow (qmax) less than or equal to 12 ml/s with void volume \>125ml. * prostate volume greater than 30 cc as determined by ultrasound, mri, or ct. * personal risk \<40% based on the university of texas san antonio prostate cancer risk calculator or having a negative prostate biopsy for cancer within the last 24 months. * able to provide written consent. * not participating in any other investigational drug or device studies. exclusion criteria: * • history of biopsy-proven prostate cancer * renal insufficiency (glomerular filtration rates (gfr) less than 40ml/min/1.73 m2 who are not already on dialysis) * prior prostate surgery or intervention, including trans-urethral resection of the prostate, balloon dilation, stent implantation, laser prostatectomy, radiation, urolift®, or hyperthermia * other bladder or urethral pathology requiring therapy, either in the past or currently, including neurogenic bladder, sphincteric abnormalities, bladder cancer, or other causes of bladder atonia. * other causes of urinary obstruction, such as strictures of urethra or ureters, not related to bph * current decompensated congestive heart failure, uncontrolled diabetes mellitus, significant respiratory disease, or known immunosuppression. * neurological disease, including multiple sclerosis, amyotrophic lateral sclerosis, parkinson's disease, and previous spinal nerve surgery * patients with platelet count \ 1.8, unless corrected for the procedure * active urinary tract infection. patients must have a negative culture within 7 days of the procedure. * allergy to iodinated contrast agents unless pre-treated by corticosteroids. * acute urinary retention. * post void residual (pvr) \> 250 ml with urodynamic evidence of atonic bladder. patients with a pvr \>250 but urodynamic testing consistent with obstruction will be allowed. * bladder stone within three months prior to the procedure. * hematuria not evaluated by urologist for causes other than bph. * previous rectal surgery (excluding hemorrhoidectomy) or history of rectal disease. * prior pelvic irradiation or radical pelvic surgery. imaging exclusion criteria: • internal iliac artery occlusion as determined by either ct or mri.

Keywords: prostate artery embolization benign prostatic hyperplasia lower urinary tract symptoms quality of life
comparison of two types of lingual fixed retainer fabricated

Conditions: Malocclusion, Angle's Class

Summary: this study includes patients who have had previous orthodontic treatments (without tooth extraction) and who have good alignment of their lower incisors. investigators will compare two types of lingual retainers made with cad-cam

this study includes patients who have had previous orthodontic treatments (without tooth extraction) and who have good alignment of their lower incisors. investigator will compare two types of lingual retainers made with cad-cam by comparing them with the traditional lingual retainers according to the following groups: 1. patients will be apply to them a lingual retainer made of fibers manufactured using cad-cam technology 2. patients will be apply to them a lingual retainer made of metal made using cad-cam technology 3. patients will be apply to them a conventional lingual retainer made of braided stainless steel wire (control group)

Eligibility criteria:
inclusion criteria: * patients with mixed dentition at age 14-24 years. they have a good alignment of the lower incisors.- have good oral and periodontal health.- exclusion criteria: patients who have a deep bite patients who have previously used retainer patients with poor oral care
precise stratification of genetic risk of ovarian function impairment

Conditions: Premature Ovarian Insufficiency; Diminished Ovarian Reserve; Early Menopause

Summary: aging is a common problem in human society at present. the fertility decline, perimenopausal symptoms and senile diseases caused by ovarian aging seriously affect women's own health, offspring's health, family and social stability, and endanger national population security. accurate stratification of genetic risk of ovarian aging has practical significance. early and accurate identification of high-risk groups of premature ovarian aging can help such women to start early protection of ovarian function, preserve fertility to a greater extent, improve fertility quality, and also be conducive to early prevention and treatment of other systemic diseases and prognosis.


Eligibility criteria:
inclusion criteria: 1. women who meet the diagnosis of premature ovarian insufficiency (poi), diminished ovarian reserve (dor) or early menopause and hope to find out the risk of premature ovarian impairment and clarify the cause of premature ovarian impairment; 1. premature ovarian insufficiency (poi): the age of female is less than 40 years old, with menopause or sparse menstruation for 4 months, and basal fsh \> 25iu / l for two consecutive times with an interval of more than 4 weeks. 2. diminshed ovarian reserve (dor): before the age of 40, the number of antral follicles in both ovaries is less than 6, or amh is less than 1.1ng/ml, or basal fsh is greater than 10 iu/l. 3. early menopause: women who enter menopause between the age of 40 and 45. 2. informed consent, voluntary test. exclusion criteria: 1. chromosome karyotype abnormality; 2. iatrogenic ovarian injury: history of radiotherapy, chemotherapy (reproductive toxic drugs such as alkylating agents) and ovarian surgery; 3. ovarian mass: there is abnormal echo in the ovary under ultrasound, and the maximum diameter is greater than 4cm. 4. pregnant and lactating women; 5. polycystic ovary syndrome, hyperprolactinemia, hyperandrogenemia, hypothyroidism, adrenal dysfunction and other endocrine diseases affect ovulation; 6. patients with cardiovascular, liver, kidney, hematopoietic system and other serious primary diseases and psychosis; 7. patients who are participating in other clinical trials or have participated in other clinical trials in the past month; 8. other patients determined by the investigator to be unsuitable for participation in this study.